124 results

• GLP-1 Lawsuit Defendants Filed Motion To Dismiss Most Claims in Plaintiffs’ Master Complaint

  January 31, 2025

  Irvin Jackson

  Two major drug manufacturers are asking a federal judge to dismiss most claims presented in GLP-1 lawsuits, which allege that side effects of Ozempic, Mounjaro and similar drugs cause severe gastrointestinal side effects.

• Increased GLP-1 Thyroid Cancer Risks May Be Product of More Intense Screening, Study Finds

  January 29, 2025

  Irvin Jackson

  The findings of a new study suggest that an apparent association between GLP-1 medications and thyroid cancer may be due to more intensive patient screening, and not a side effect of the drugs themselves.

• Side Effects of Ozempic, Other GLP-1 Drugs Are Mixed, With Net Benefits Overall: Study

  January 22, 2025

  Irvin Jackson

  A new study attempts to categorize the benefits and risks of drugs like Ozempic and Mounjaro, finding that they decrease the risk of many metabolic health problems due to the weight lost, while warning of potential gastrointestinal problems such as stomach paralysis, and an increased risk of acute pancreatitis.

• Evidentiary Hearing for “Cross Cutting” Ozempic Lawsuit Causation Issues Scheduled for May 2025

  January 3, 2025

  Irvin Jackson

  A federal judge has scheduled a hearing in May to review evidence linking Ozempic and similar drugs to gastrointestinal problems, such as gastroparesis and intestinal obstruction.

• MDL Judge Schedules Ozempic Lawsuit Status Conferences Throughout 2025

  December 5, 2024

  Irvin Jackson

  With the first Ozempic lawsuit bellwether trials not expected to begin until at least late 2026 or early 2027, the court will address motions to dismiss and other “cross cutting” issues in 2025.

• Ozempic Ileus Lawsuit Filed by Woman Left With Gastrointestinal Problems After Receiving Injections for 2 Years

  November 25, 2024

  Irvin Jackson

  Alabama woman is seeking both compensatory and punitive damages, claiming she suffered multiple gastrointestinal problems due to the side effects of the Novo Nordisk diabetes drug, Ozempic.

• Master Complaint Outlines Allegations in Ozempic, Wegovy, Mounjaro Lawsuits in MDL

  November 15, 2024

  Irvin Jackson

  Plaintiffs pursuing GLP-1 injury lawsuits have filed a Master Complaint outlining common allegations being pursued against Novo Nordisk and Eli Lilly over their diabetes and weight loss drugs, including Ozempic, Wegovy, Mounjaro and others.

• Wegovy Lawsuit Indicates Ileus, Gallstones, Other Side Effects Caused by Weight Loss Drug

  November 13, 2024

  Irvin Jackson

  A West Virginia woman indicates that Novo Nordisk's failure to warn about potential side effects of Wegovy caused her to develop ileus, intense pain and the loss of her gallbladder.

• Bariatric Surgery Rates Down by 26% in Recent Years: Report

  November 12, 2024

  Martha Garcia

  Study suggests that many patients seeking weight loss are foregoing bariatric surgeries, and instead moving toward the use of GLP-1 medications like Ozempic, Wegovy and Mounjaro.

• Pulmonary Aspiration Warning Added to Ozempic, Wegovy, Mounjaro and Other GLP-1s Regarding Use Before Anesthesia or Deep Sedation

  November 7, 2024

  Irvin Jackson

  The FDA is requiring new label warnings for Ozempic, Wegovy, Mounjaro and all other GLP-1 drugs, indicating they may cause pulmonary aspiration during surgery.